Format
Sort by

Send to

Choose Destination

Search Tip

Sort by Best Match to display results from highest to lowest relevance to your search terms.

Try it Now

Search results

Items: 1 to 20 of 125

1.

CFTR Modulator Therapies in Pediatric Cystic Fibrosis: Focus on Ivacaftor.

Kramer EL, Clancy JP.

Expert Opin Orphan Drugs. 2016 Oct;4(10):1033-1042. doi: 10.1080/21678707.2016.1226800.

PMID:
28042521
2.

Microbiological efficacy of early MRSA treatment in cystic fibrosis in a randomised controlled trial.

Muhlebach MS, Beckett V, Popowitch E, Miller MB, Baines A, Mayer-Hamblett N, Zemanick ET, Hoover WC, VanDalfsen JM, Campbell P, Goss CH; STAR-too study team..

Thorax. 2016 Nov 15. pii: thoraxjnl-2016-208949. doi: 10.1136/thoraxjnl-2016-208949. [Epub ahead of print]

PMID:
27852955
3.

Feasibility, tolerability and safety of pediatric hyperpolarized 129Xe magnetic resonance imaging in healthy volunteers and children with cystic fibrosis.

Walkup LL, Thomen RP, Akinyi TG, Watters E, Ruppert K, Clancy JP, Woods JC, Cleveland ZI.

Pediatr Radiol. 2016 Nov;46(12):1651-1662.

PMID:
27492388
4.

Constrictive Bronchiolitis in Cystic Fibrosis Adolescents with Refractory Pulmonary Decline.

Harris WT, Boyd JT, McPhail GL, Brody AS, Szczesniak RD, Korbee LL, Baker ML, Clancy JP.

Ann Am Thorac Soc. 2016 Dec;13(12):2174-2183.

PMID:
27684511
5.

PharmGKB summary: ivacaftor pathway, pharmacokinetics/pharmacodynamics.

Fohner AE, McDonagh EM, Clancy JP, Whirl Carrillo M, Altman RB, Klein TE.

Pharmacogenet Genomics. 2017 Jan;27(1):39-42. No abstract available.

PMID:
27636560
6.

Urinary kidney injury biomarkers and tobramycin clearance among children and young adults with cystic fibrosis: a population pharmacokinetic analysis.

Downes KJ, Dong M, Fukuda T, Clancy JP, Haffner C, Bennett MR, Vinks AA, Goldstein SL.

J Antimicrob Chemother. 2017 Jan;72(1):254-260.

PMID:
27585963
7.

Ultrashort Echo-Time Magnetic Resonance Imaging Is a Sensitive Method for the Evaluation of Early Cystic Fibrosis Lung Disease.

Roach DJ, Crémillieux Y, Fleck RJ, Brody AS, Serai SD, Szczesniak RD, Kerlakian S, Clancy JP, Woods JC.

Ann Am Thorac Soc. 2016 Nov;13(11):1923-1931.

PMID:
27551814
8.

Bayesian Ensemble Trees (BET) for Clustering and Prediction in Heterogeneous Data.

Duan LL, Clancy JP, Szczesniak RD.

J Comput Graph Stat. 2016;25(3):748-761.

9.

Hyperpolarized 129Xe for investigation of mild cystic fibrosis lung disease in pediatric patients.

Thomen RP, Walkup LL, Roach DJ, Cleveland ZI, Clancy JP, Woods JC.

J Cyst Fibros. 2016 Jul 28. pii: S1569-1993(16)30565-3. doi: 10.1016/j.jcf.2016.07.008. [Epub ahead of print]

PMID:
27477942
10.

Continuous alternating inhaled antibiotics for chronic pseudomonal infection in cystic fibrosis.

Flume PA, Clancy JP, Retsch-Bogart GZ, Tullis DE, Bresnik M, Derchak PA, Lewis SA, Ramsey BW.

J Cyst Fibros. 2016 Nov;15(6):809-815. doi: 10.1016/j.jcf.2016.05.001.

PMID:
27233377
11.

Cystic Fibrosis and Its Management Through Established and Emerging Therapies.

Spielberg DR, Clancy JP.

Annu Rev Genomics Hum Genet. 2016 Aug 31;17:155-75. doi: 10.1146/annurev-genom-090314-050024.

PMID:
26905785
12.

Cystic Fibrosis Transmembrane Conductance Regulator Function in Airway Smooth Muscle. A Novel Role in Cystic Fibrosis Airway Obstruction.

Clancy JP.

Am J Respir Crit Care Med. 2016 Feb 15;193(4):352-3. doi: 10.1164/rccm.201510-2088ED. No abstract available.

PMID:
26871669
13.

Diagnostic Testing in Cystic Fibrosis.

Brewington J, Clancy JP.

Clin Chest Med. 2016 Mar;37(1):31-46. doi: 10.1016/j.ccm.2015.10.005. Review.

PMID:
26857766
14.
15.

Predicting future lung function decline in cystic fibrosis patients: Statistical methods and clinical connections.

Szczesniak RD, McPhail GL, Li D, Amin RS, Clancy JP.

Pediatr Pulmonol. 2016 Feb;51(2):217-8. doi: 10.1002/ppul.23357. No abstract available.

16.

Lumacaftor alone and combined with ivacaftor: preclinical and clinical trial experience of F508del CFTR correction.

Brewington JJ, McPhail GL, Clancy JP.

Expert Rev Respir Med. 2016;10(1):5-17. doi: 10.1586/17476348.2016.1122527.

PMID:
26581802
17.
18.

Matrix Metalloproteinase-9 Mediates RSV Infection in Vitro and in Vivo.

Kong MY, Whitley RJ, Peng N, Oster R, Schoeb TR, Sullender W, Ambalavanan N, Clancy JP, Gaggar A, Blalock JE.

Viruses. 2015 Jul 30;7(8):4230-53. doi: 10.3390/v7082817. Erratum in: Viruses. 2015 Oct;7(10):5609.

19.

Capturing the Direct Binding of CFTR Correctors to CFTR by Using Click Chemistry.

Sinha C, Zhang W, Moon CS, Actis M, Yarlagadda S, Arora K, Woodroofe K, Clancy JP, Lin S, Ziady AG, Frizzell R, Fujii N, Naren AP.

Chembiochem. 2015 Sep 21;16(14):2017-22. doi: 10.1002/cbic.201500123.

20.

Concentration of fractional excretion of nitric oxide (FENO): A potential airway biomarker of restored CFTR function.

Kotha K, Szczesniak RD, Naren AP, Fenchel MC, Duan LL, McPhail GL, Clancy JP.

J Cyst Fibros. 2015 Nov;14(6):733-40. doi: 10.1016/j.jcf.2015.07.002.

Items per page

Supplemental Content

Loading ...
Support Center